

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Immune responses to COVID-19 vaccines, aerosol generating procedures, real world effectiveness of oral antivirals

Peer reviewed journals featured:

- Narrative reviews on:
 - Immune responses to COVID-19 vaccines [here](#)
 - Defining aerosol generating procedures [here](#)
 - Anti-inflammatory agents for 'at-home' management of COVID-19 [here](#)
- Observational studies on:
 - Real-world effectiveness of early oral antiviral use in hospitalised COVID-19 patients in Hong Kong [here](#) and associated commentary [here](#)
 - Somatic symptom disorder in patients with post-COVID-19 neurological symptoms [here](#)
 - Accuracy of 2 rapid antigen tests during 3 phases of SARS-CoV-2 variants [here](#)
 - COVID-19 infection and glasses wear [here](#) and associated commentary [here](#)
 - SARS-CoV-2 results in self-collected nasal swabs vs swabs collected by healthcare workers in children and adolescents [here](#) and associated editorial [here](#)
 - Alveolar damage patterns in fatal COVID-19 [here](#)
 - Electrolyte imbalances in predicting severity of COVID-19 in hospitalised patients [here](#)
 - Comirnaty (Pfizer) vaccination and reported incidence of post-COVID-19 symptoms [here](#)
 - Dysregulated naïve B cells and de novo autoreactivity in severe COVID-19 [here](#)
 - SARS-CoV-2 nucleocapsid antigen level and outcomes in hospitalised patients [here](#)
 - Fatality assessment and variant risk monitoring for COVID-19 [here](#)
- Commentary on SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during Omicron outbreak [here](#) and [here](#)

Letters and correspondence discussed:

- Airway-resident T cells from unexposed individuals cross-recognise SARS-CoV-2 [here](#)
- Risk of BA.5 infection among persons exposed to previous SARS-CoV-2 variants [here](#)
- Remdesivir in patients with severe kidney dysfunction [here](#)
- Administration of anti-SARS-CoV-2 monoclonal antibodies after US FDA deauthorisation [here](#)
- Analysis of neutralising antibody levels in children and adolescents up to 16 months after SARS-CoV-2 infection [here](#) and associated editorial [here](#)
- Variation in reported SARS-CoV-2 cases after testing policy changes in the UK [here](#)

Pre-peer review articles featured:

- Omicron BA.2.75 variant infectivity compared with pre-existing variants [here](#)
- Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination [here](#)
- Long COVID prevalence and risk factors in children and adolescents [here](#)
- Metformin and COVID-19 severity in patients with prediabetes [here](#)
- Effectiveness of endurance training rehabilitation after hospitalisation in intensive care for COVID-19-related acute respiratory distress syndrome on dyspnoea (RECOVER) [here](#)
- A living systematic review update with controlled studies on characterising long COVID [here](#)
- Immune protection against SARS-CoV-2 re-infection and immune imprinting [here](#)
- RNA polymerase inhibitor enisamium for treatment of moderate COVID-19 patients [here](#)
- Predicting risk of death or hospitalisation in COVID-19 adults in England [here](#)
- Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave [here](#)

Guidance and reports

- The World Health Organization released its weekly COVID-19 epidemiological report [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- Australian Technical Advisory Group on Immunisation (ATAGI) recommendation on the use of Novavax vaccine for adolescents aged 12-17 years [here](#)

News and blogs

- Asymptomatic testing is “paused” in England’s hospitals and care homes [here](#)
- Could long COVID be linked to herpes viruses? [here](#)
- COVID vaccines slash risk of spreading Omicron and so does previous infection [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).